Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE
2020-001177-78Phase 2Completed
- Sponsor
- University of Utah
- Start
- Apr 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of certolizumab pegol in antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and Pregnancy-related complication, sponsored by University of Utah. Primary endpoints: Composite adverse pregnancy outcomes associated with poor placentation and Angiogenic markers of placental vascularization. Started Apr 2020; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
antiphospholipid syndrome (APS)systemic lupus erythematosus (SLE)Pregnancy-related complication
Beyond the preview
Go deeper on 2020-001177-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001177-78.